Results 31 to 40 of about 27,057 (223)
Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]
, 2019 Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela +1 more
core +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2014 Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow ...
Cesar Cilento Ponce +3 more
doaj +1 more source
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]
, 2019 Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Annunziata, M. +14 more
core +1 more source
Treatment of primary myelofibrosis
Turkish Journal of Hematology, 2009 Şinasi Özsoylu
doaj +2 more sources
Targeted sequencing of candidate gene regions for myelofibrosis in dogs
Journal of Veterinary Internal Medicine, 2022 Background Myelofibrosis often lacks an identifiable cause in dogs. In humans, most primary myelofibrosis cases develop secondary to driver mutations in JAK2, CALR, or MPL.
Amelia G. Campbell +7 more
doaj +1 more source
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]
, 2020 Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M +6 more
core
Primary autoimmune myelofibrosis: A case report in a child
eJHaem, 2020 Autoimmune myelofibrosis (AIMF) is an uncommon cause of myelofibrosis associated with favorable outcome. Primary AIMF, AIMF without a known systemic autoimmune disorder, has been described in adults, but never in children. Here, we present, for the first
Zufit Hexner‐Erlichman +7 more
doaj +1 more source
Haematologica, 2011 Risk stratification in primary myelofibrosis is currently based on two international prognostic scoring systems, neither of which takes into consideration red blood cell transfusion-dependency.
Chiara Elena +9 more
doaj +1 more source
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]
, 2016 The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core +2 more sources
How I Diagnose Primary Myelofibrosis
American Journal of Clinical Pathology, 2022 Abstract Objectives Primary myelofibrosis (PMF) is a BCR/ABL1-negative myeloproliferative neoplasm (MPN) with a shorter overall survival and a higher leukemic transformation than other BCR/ABL1-negative MPNs.
Sonam, Prakash, Attilio, Orazi
openaire +2 more sources